Epidemiology of Environmental Exposure and Malignant Mesothelioma

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Survival after Sublobar Resection for Early-Stage Lung Cancer: Methodological Obstacles in Comparing the Efficacy to Lobectomy Emanuela Taioli, MD, PhD,

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

Epidemiology of Environmental Exposure and Malignant Mesothelioma

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Ting-Yuan David Cheng, PhD, Susanna M. Cramb, PhD, Peter D

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

An Unusual Presentation of Malignant Pleural Mesothelioma

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Nodal Upstaging Is More Common with Thoracotomy than with VATS During Lobectomy for Early-Stage Lung Cancer: An Analysis from the National Cancer Data.

Emanuela Taioli, MD, PhD, Andrea S

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Frank Detterbeck, MD Journal of Thoracic Oncology

Boundary between N1 and N2 Lymph Node Descriptors in the Subcarinal Zone in Lower Lobe Lung Cancer: A Brief Report Mitsuhiro Isaka, MD, Haruhiko Kondo,

Stefano Occhipinti, PhD, Jeff Dunn, PhD, Dianne L

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

David Feller-Kopman, MD, Shan Liu, PhD, Benjamin P

Variations in Receipt of Curative-Intent Surgery for Early-Stage Non–Small Cell Lung Cancer (NSCLC) by State Helmneh M. Sineshaw, MD, MPH, Xiao-Cheng.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Prospective Study on Functional Results After Lung-Sparing Radical Pleurectomy in the Management of Malignant Pleural Mesothelioma Servet Bölükbas, MD,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

“The Best-Laid Plans … Often go Awry …”

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study Gunnar Hillerdal, MD, PhD, Jens.

Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non–Small Cell Lung Cancer and Bone Metastases:

A Primer on Health Economic Evaluations in Thoracic Oncology

Mirror Mirror on the Wall, Who Is the Fairest of Them All

The Number of Pulmonary Metastases: Influence on Practice and Outcome

Nivolumab-Induced Granulomatous Inflammation of the Pleura

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Pulmonary Resection for Metastases from Colorectal Cancer

International Thymic Malignancies Interest Group: A Way Forward

European Lung Cancer Conference (ELCC) 2016 Organisation

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

Epidemiology of Thymoma and Associated Malignancies

Who should decide margin length in pulmonary excision of lung cancer?

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Debby P. M. van den Bogaert, MD, Ellen M

Robert Comis, MD, The Passing of a “Lung Man”

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

Epidemiology of Environmental Exposure and Malignant Mesothelioma Bian Liu, PhD, Maaike van Gerwen, MD, Stefano Bonassi, PhD, Emanuela Taioli, MD, PhD Journal of Thoracic Oncology Volume 12, Issue 7, Pages 1031-1045 (July 2017) DOI: 10.1016/j.jtho.2017.04.002 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Flowchart of the studies’ selection. Journal of Thoracic Oncology 2017 12, 1031-1045DOI: (10.1016/j.jtho.2017.04.002) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Relative quality expressed as z scores (y axis) of the studies reviewed (x axis, in the same order as they appear in Table 1). Dots are colored according to the country of origin and sized according to the total sample size of the study. UK, United Kingdom; USA, United States. Journal of Thoracic Oncology 2017 12, 1031-1045DOI: (10.1016/j.jtho.2017.04.002) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Geographic locations of the reviewed studies with the numbers of studies from each location. Journal of Thoracic Oncology 2017 12, 1031-1045DOI: (10.1016/j.jtho.2017.04.002) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Ratios of male to female patients among malignant mesothelioma cases reporting overall exposure (occupational and environmental) and environmental exposure (EE) to asbestos. Journal of Thoracic Oncology 2017 12, 1031-1045DOI: (10.1016/j.jtho.2017.04.002) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 5 Percentage of malignant mesothelioma (MM) cases with nonidentifiable asbestos exposure. Journal of Thoracic Oncology 2017 12, 1031-1045DOI: (10.1016/j.jtho.2017.04.002) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions